Clinical Trial Update: ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ONC-201 in combination with weekly paclitaxel for platinum-refractory or resistant ovarian cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• ONC-201 (ONC-201)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Ira Winer | Conditions: Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Status: RECRUITING